Company intelligence / Profile preview

Hangzhou Shengnuo Hongjian Biotechnology

Hangzhou, Zhejiang, Chinasec.gov ↗

Ownership: Private
Development stage: Other

Overview

Hangzhou Shengnuo Hongjian Biotechnology is an active biotechnology company specializing in nucleic acid raw materials and CDMO services for RNA therapeutics. The company provides end-to-end solutions for the development and manufacturing of oligonucleotide-based drugs, with world-leading capacity for phosphoramidites and nucleotides.

Modalities: RNA therapyOligonucleotideNucleic acid-based drugs
Industry: Contract Manufacturing Organization

Partnerships

Not specified in available sources; likely partners with global biotech/pharma companies as a CDMO

Beyond the preview

Go deeper on Hangzhou Shengnuo Hongjian Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Shengnuo Hongjian Biotechnology.

Explore the full profile